KEAMANAN PENGGUNAAN OBAT PADA KEHAMILAN DI RUMAH SAKIT SWASTA YOGYAKARTA
DOI:
https://doi.org/10.36387/jiis.v10i2.2485Keywords:
Drug safety, FDA category, Pregnancy, HospitalAbstract
Pregnancy is a special physiological condition in which the use of medication is often unavoidable. However, the risks of teratogenicity and drug safety require careful evaluation to minimize risks to both mother and fetus. This study aims to evaluate the safety of drug use based on FDA (Food and Drug Administration) categories in pregnant inpatients at a private hospital in Yogyakarta. The study uses a descriptive observational method with a cross- sectional design, analyzing 141 inpatient medical records from 2022. The analyzed data includes patient demographics, diagnoses, drug safety, and dosages. Inclusion criteria were pregnant inpatients treated with or without pregnancy emergencies; exclusion criteria were patients giving birth or experiencing abortion. Descriptive results (using Microsoft Excel) showed most pregnant inpatients were aged 20-35 years (80.14%), hospitalized during the first trimester (49.65%), had no comorbidities (90.07%), no emergency pregnancy conditions (82.27%), and a length of stay under 4 days (72.34%). The most common diagnosis was hyperemesis gravidarum (41.84%), with predominant use of multivitamins (16.18%) and antiemetics (14.91%). The safety of drugs in inpatients was categorized as A (18.80%), B (34.34%), C (36.86%), D (2.26%), and N (6.77%), with appropriate dosage usage (96,30%). The study concludes that drug use was dominated by category C, and no use of category X drugs was found. The most used drugs were folic acid multivitamins and iron supplements for increasing blood levels.
References
Al-Hamimi, J. Z., & Al Balushi, K. A. (2016). Patterns of prescription drugs use among pregnant women at Sultan Qaboos University Hospital and Sultan Qaboos University Hospital Family and Community Medicine Clinic, Oman. J Pharm Bioallied Sci, 8(4), 309-313. https://doi.org/10.4103/0975-7406.199347
Alema, N. M., Semagn, G., Melesse, S., Araya, E. M., Gebremedhin, H., Demsie, D. G., Asgedom, S. W., & Weldekidan, E. (2020). Patterns and determinants of prescribed drug use among pregnant women in Adigrat general hospital, northern Ethiopia: a cross-sectional study. BMC Pregnancy Childbirth, 20(1), 624. https://doi.org/10.1186/s12884-020-03327-7
Andersen, S. L. (2025). An update on the safety of antithyroid drugs in pregnancy: the power of real-world data. Expert Opinion on Drug Safety, 1-11. https://doi.org/10.1080/14740338.2025.2564073
Atkinson, A. J., Jr. (2018). Augmented renal clearance. Transl Clin Pharmacol, 26(3), 111-114. https://doi.org/10.12793/tcp.2018.26.3.111
Attali, E., & Yogev, Y. (2021). The impact of advanced maternal age on pregnancy outcome. Best Practice & Research Clinical Obstetrics & Gynaecology, 70, 2-9. https://doi.org/https://doi.org/10.1016/j.bpobgyn.2020.06.006
Balon, M., Tessier, S., Damase-Michel, C., Cottin, J., Lambert, A., Thompson, M. A., Benevent, J., & Lacroix, I. (2023). Adverse drug reactions in pregnant women: Do they differ from those in non-pregnant women of childbearing age? Therapie, 78(2), 165-173. https://doi.org/10.1016/j.therap.2022.11.005
Bandoli, G., Palmsten, K., Forbess Smith, C. J., & Chambers, C. D. (2017). A Review of Systemic Corticosteroid Use in Pregnancy and the Risk of Select Pregnancy and Birth Outcomes. Rheum Dis Clin North Am, 43(3), 489-502. https://doi.org/10.1016/j.rdc.2017.04.013
Feghali, M., Venkataramanan, R., & Caritis, S. (2015). Pharmacokinetics of drugs in pregnancy. Semin Perinatol 39(7), 512-519.
https://doi.org/10.1053/j.semperi.2015.08.003
Food, U. S., & Administration, D. (2019, August 1, 2019). FDA issues final rule on changes to pregnancy and lactation labeling information for prescription drug and biological products. U.S. Food and Drug Administration. https://www.fda.gov/drugs/labeling/pregnancy-and-lactation-labeling-drugs- final-rule
Jansen, L. A. W., Nijsten, K., Limpens, J., van Eekelen, R., Koot, M. H., Grooten, I. J., Roseboom, T. J., & Painter, R. C. (2023). Perinatal outcomes of infants born to mothers with hyperemesis gravidarum: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol, 284, 30-51.
https://doi.org/10.1016/j.ejogrb.2023.03.004
Kemp, M. W., Newnham, J. P., Challis, J. G., Jobe, A. H., & Stock, S. J. (2016). The clinical use of corticosteroids in pregnancy. Hum Reprod Update, 22(2), 240-259. https://doi.org/10.1093/humupd/dmv047
Kim, J. H., & Scialli, A. R. (2011). Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci, 122(1), 1-6. https://doi.org/10.1093/toxsci/kfr088
McParlin, C., O'Donnell, A., Robson, S. C., Beyer, F., Moloney, E., Bryant, A., Bradley, J., Muirhead, C. R., Nelson-Piercy, C., Newbury-Birch, D., Norman, J., Shaw, C., Simpson, E., Swallow, B., Yates, L., & Vale, L. (2016). Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review. Jama, 316(13), 1392-1401. https://doi.org/10.1001/jama.2016.14337
Neiger, R. (2017). Long-Term Effects of Pregnancy Complications on Maternal Health: A Review. J Clin Med, 6(8). https://doi.org/10.3390/jcm6080076
Nguyen, C. T., Sasso, E. B., Barton, L., & Mestman, J. H. (2018). Graves' hyperthyroidism in pregnancy: a clinical review. Clin Diabetes Endocrinol, 4, 4.
https://doi.org/10.1186/s40842-018-0054-7
Patel, S., Patel, K., Patel, H., Gajjar, U., Deshpande, S., & Mathuria, A. (2021). Evaluation of Usage of Drugs in Pregnancy at Private Hospitals. Indian Journal of Pharmacy Practice, 14, 259-267. https://doi.org/10.5530/ijopp.14.4.53
Porgador, O., Sheiner, E., Pariente, G., & Wainstock, T. (2024). Pregnancy outcomes by hyperemesis gravidarum severity and time of diagnosis: A retrospective cohort study. Int Gynaecol Obstet, 167(3), 1075-1083. https://doi.org/10.1002/ijgo.15760
Sarayani, A., Albogami, Y., Thai, T. N., Smolinski, N. E., Patel, P., Wang, Y., Nduaguba, S., Rasmussen, S. A., & Winterstein, A. G. (2022). Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies. American Journal of Obstetrics and Gynecology, 227(2), 263.e261-263.e238. https://doi.org/https://doi.org/10.1016/j.ajog.2022.01.004
Sukumaran, D., Cherian, A. G., Das, S., Winston, A. B., Kumar, A., & Shanthi Fx, M. (2016). Drug Prescribing Pattern During Intranatal Period in a Secondary Care Hospital in South India: A Retrospective Study. J Prim Care Community Health, 7(2), 113-117. https://doi.org/10.1177/2150131915627768
Weld, E. D., Bailey, T. C., & Waitt, C. (2022). Ethical issues in therapeutic use and research in pregnant and breastfeeding women. Br J Clin Pharmacol, 88(1), 7-21
Downloads
Published
Issue
Section
License
Copyright (c) 2025 JIIS (Jurnal Ilmiah Ibnu Sina): Ilmu Farmasi dan Kesehatan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
